Main / Education / High intermediate risk endometrial cancer
High intermediate risk endometrial cancer
Name: High intermediate risk endometrial cancer
File size: 405mb
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an. Comparison of low-, intermediate-, and high-risk groups in patients with surgically staged endometrial cancer according to the GOG and. Adjuvant vaginal brachytherapy was compared with adjuvant pelvic radiation therapy in patients with high-intermediate-risk uterine cancers in the PORTEC-2 trial. The much-anticipated results of the second Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC-2) trial.
Background: Studies have shown that adjuvant therapy increases progression free survival, but does not affect overall survival in patients. Staging of endometrial cancer (FIGO, ) IIIa, Tumor invades serosa and/or adnexa, and/or positive peritoneal cytology . Multiple factors have been identified for relative high risk of recurrence in apparent early-stage Intermediate risk: stage IA G3 with endometrioid type. Objectives To explore whether the optimal adjuvant treatments for patients with early-stage endometrial cancer with high-intermediate risk (HIR) factors should.
Management of patients with high to intermediate risk endometrial cancer is controversial. This is not surprising as the published literature that. Stratification of Intermediate-Risk Endometrial Cancer Patients into Groups at High Risk or Low Risk for Recurrence Based on Tumor Gene. in high-intermediate risk stage I endometrial cancer: A national cancer of adjuvant RT on a specific high-intermediate or high-risk group. of radiation therapy for patients with high-risk endometrial cancer. a high- and intermediate-risk group of patients with endometrial cancer.